Table 1.
Therapeutic use and evaluation of Dol-10 in various antitumor research.
| Therapeutic Use | Development State | Evaluation Outcome * | Reference |
|---|---|---|---|
| Anti-lymphoma | Preclinical | ++ | [36,49,50,51] |
| Anti-lung cancer | Preclinical | ++ | [37] |
| Anti-ovarian carcinoma | Phase II | + | [48] |
| Anti-prostate cancer | Preclinical, phase II | ++, + (respectively) | [36,52] |
| Anti-soft tissue sarcoma | Phase II | - | [53] |
| Anti-breast cancer | Phase II | - | [54] |
| Anti-hepatobiliary pancreatic carcinoma | Phase II | - | [55] |
*-, almost no objective curative effect and toxic symptoms were observed; +, positive; ++, strongly positive.